



**Medical Tactile, Inc.**  
SureTouch PreMammogram Exam

**LOS ANGELES, CA** – Sept.14, 2007 – Medical Tactile Incorporated (MTI) has received European approval for its SureTouch™ Visual Mapping System, which is a unique digital sensing device that assists healthcare professionals in screening for breast cancer during routine exams, greatly increasing the chances of early diagnosis of breast cancer in women.

Obtaining the CE marking is mandatory before certain products can be sold in Europe. Approval to display the marking means that the manufacturers of SureTouch™ have demonstrated that its product conforms to the European community's rigorous health and safety standards. Compliance with requirements of the European directives was determined by examiners in Norway.

"Receiving certification for the CE Mark allows MTI to deliver our state-of-the-art clinical breast exam technology platform and software to medical professionals throughout the European community," said Dave Ables, MTI's chief technology officer. "Because SureTouch™ can detect lesions as small as 5mm in size and, at the same time, documents all findings during the clinical breast exam, we believe it will occupy a strong position in the European market for general practitioners, OBGYN and breast surgeons."

SureTouch™ has been approved by the U.S. Food and Drug Administration (FDA) and on the market since late 2005. The FDA granted approval for export of SureTouch™ to international markets in June 2007 and, with the CE Mark certification, it is now commercially available internationally.

In two years time, doctors in the U.S. and the Netherlands have chosen it for their patients. Not only is it safe; a SureTouch™ exam is comfortable. Unlike a mammogram exam, where the breast is compressed, SureTouch™ is a simple hand-held device that is placed on the breast. The image is then reflected on a laptop computer screen. The exam produces a visual map of the breast that, if a mass is detected, will show its estimated size, shape, hardness and location. SureTouch™ allows the earliest possible detection, therefore helps to save lives.

A two-year study of SureTouch™, funded by the National Institute of Health, documented the technology's extraordinary results for identifying and mapping breast lesions. The researchers involved in the project reported their findings in the American Journal of Surgery.